In June 2016, the breakthrough development of precision medicine research on cerebrovascular disease by the team of Prof. Wang Yongjun, Head of the Institute of Stroke of Beijing Institute For Brain Disorders and professor of Beijing Tian Tan Hospital, Capital Medical University, was published on Journal of the American Medical Association online. The research shows that the clinical effect of clopidogrel treatment for patients with acute ischemic minor stroke or transient cerebral ischemic attack is reduced by carrying CYP2C19 loss of function alleles. This is the first time the world's top medical journal publishes the precision medicine research achievements of cerebrovascular disease in China, and will have a significant impact worldwide.
